Jamjoom Pharma Assembly Approves Competitive Business Controls and Standards Policy

Jamjoom Pharmaceuticals Factory Company (the “Company”) announced on Thursday the results of the Ordinary General Assembly Meeting (First Meeting) held on Wednesday, where the items included approval of the Company’s competitive business controls and standards policy.

The rest of the items of the voting results on the Assembly’s agenda were as follows:

– Approval of the Board of Directors Membership Policy, Standards, and Procedures.

– Approval of the appointment of (Ernst and Young) as the external auditor for the Company from among the candidates and based on the Audit Committee’s recommendation; to examine, review and audit the financial statements for the financial year 2025, the second and third quarters of 2025, and the first quarter of 2026, with a total fee of SAR 880,000.